Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

gastic cancer

- PMLiVE

Astellas and PeptiDream announce protein degrader research collaboration

Protein degrader drugs have been proposed as a way to address ‘undruggable’ targets

- PMLiVE

Alliance for Genomic Discovery announces its five founding biopharma members

The AGD aims to accelerate drug development and expand the diversity of genomic data

- PMLiVE

Amgen’s supplemental Biologics License Application for Blincyto approved by FDA

The approval for the leukaemia drug was supported by additional data from two phase 3 studies

- PMLiVE

Pfizer’s Talzenna combination receives FDA approval for metastatic prostate cancer

Up to 20% of patients develop metastatic prostate cancer within five to seven years of diagnosis

- PMLiVE

Astellas and Cullgen announce protein degrader partnership worth up to $1.9bn

The companies will use Cullgen’s protein degradation platform to discover multiple candidates

- PMLiVE

Amgen’s Lumakras shows promise in phase 3 lung cancer study

The company has also presented results from a study of Lumakras in colorectal cancer

- PMLiVE

Amgen reports positive results for inflammatory disease drug Otezla in psoriatic arthritis

The inflammatory condition is estimated to affect nearly 38 million people worldwide

- PMLiVE

Astellas Pharma’s non-hormonal menopause drug granted FDA approval

Vasomotor symptoms affect up to 80% of menopausal individuals in the US

- PMLiVE

Amgen and TScan Therapeutics partner to identify new Crohn’s disease targets

Inflammatory bowel disease affects nearly one in every 100 people in the US

- PMLiVE

AstraZeneca and Amgen’s Tezspire recommended by NICE for severe asthma

An estimated 98,000 patients with severe uncontrolled asthma may be eligible for the new treatment

- PMLiVE

Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study

The treatment is already approved in the US for three disease states of prostate cancer

- PMLiVE

Results for Astellas’ non-hormonal menopause drug published in The Lancet

Symptoms such as hot flashes and night sweats are the most common symptoms of menopause

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links